Duke, DCRI partner with Boehringer Ingelheim on new COPD study

April 27, 2017

Read the original article on Triangle Business Journal. Duke University’s MURDOCK Study and Duke Clinical Research Institute (DCRI) will collaborate with Boehringer Ingelheim Pharmaceuticals on a new chronic obstructive pulmonary disease (COPD) study. Based in Kannapolis, MURDOCK stands for the Measurement to Understand the Reclassification of Disease of Cabarrus/Kannapolis. The new study will involve following […]

Study launched to better understand real-world impact and progression of COPD

April 07, 2017

Duke Clinical Research Institute, Duke University’s MURDOCK Study and Boehringer Ingelheim Pharmaceuticals Launch Innovative Clinical Research Study KANNAPOLIS, N.C. and RIDGEFIELD, Conn.—April 7, 2017—Duke University’s MURDOCK Study, the Duke Clinical Research Institute (DCRI) and Boehringer Ingelheim Pharmaceuticals Inc. announced today the launch of a new collaborative research effort to closely follow 850 people living with […]